raloxifene hydrochloride has been researched along with epigallocatechin gallate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosengren, RJ; Stuart, EC | 1 |
| Jarvis, RM; Rosengren, RJ; Stuart, EC | 1 |
2 other study(ies) available for raloxifene hydrochloride and epigallocatechin gallate
| Article | Year |
|---|---|
The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells.
Topics: Apoptosis; Blotting, Western; Catechin; Cell Cycle; Cell Line, Tumor; Culture Media; ErbB Receptors; Female; Flow Cytometry; Glucuronosyltransferase; Humans; Neuroprotective Agents; Phosphorylation; Proto-Oncogene Proteins c-akt; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2008 |
In vitro mechanism of action for the cytotoxicity elicited by the combination of epigallocatechin gallate and raloxifene in MDA-MB-231 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catechin; Cell Line, Tumor; ErbB Receptors; Estrogen Receptor alpha; Female; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Raloxifene Hydrochloride; Receptor, ErbB-2; Ribosomal Protein S6 Kinases; Selective Estrogen Receptor Modulators; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transcription Factor RelA | 2010 |